
APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS GENERAL ADMINISTRATION
INVENTO ENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 1 of 31



1/31

## FIG. 1

FIG. 2
The Enterohepatic Circulation with Key Transporter Proteins
Mediating Bile Acid Circulation



3

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATITUTE OF DRUGS AFTER ORAL ADMINISTRATION: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 2 of 31

2/31

## FIG. 3

Bile Acid Conjugates of HMG-CoA Reductase Inhibitor

FIG. 4

 $Z = CO_2H, P(0)(OR^{19})(OH)$ 

HO  $R_1$ **(VII)**  $Z = SO_3H, P(O)(OR^{19})(OH),$  $OSO_3H$ ,  $OP(O)(OR^{19})(OH)$ 

> HO<sub>m,</sub> (VIII)

> > R1 =  $\alpha$ -OH; R2 =  $\alpha$ -OH (Cholate)

R1 =  $\beta$ -OH; R2 = H (Ursodeoxycholate) R1 =  $\alpha$ -OH; R2 = H (Chenodeoxycholate)

R1 = H; R2 =  $\alpha$ -OH (Deoxycholate)

R1 =  $\beta$ -OH; R2 =  $\alpha$ -OH (Ursocholate)

R1 = H; R2 = H (Lithocholate)

. Oggyetes . oeosoe

OG97E4E5.CEOSOE

$$R_{1}$$
 $R_{2}$ 
 $R_{3}$ 
 $R_{1}$ 
 $R_{1}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{1}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{1}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{1}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{1}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{6}$ 
 $R_{9}$ 
 $R_{10}$ 
 $R_$ 

R1 =  $\alpha$ -OH; R2 =  $\alpha$ -OH (Cholate) R1 =  $\beta$ -OH; R2 = H (Ursodeoxycholate) R1 =  $\alpha$ -OH; R2 = H (Chenodeoxycholate) R1 = H; R2 =  $\alpha$ -OH (Deoxycholate) R1 =  $\beta$ -OH; R2 =  $\alpha$ -OH (Ursocholate)

R1 = H; R2 = H (Lithocholate)

PROVIDING SUSTAINED SYSTEMIC CONCENTR

S OF DRUGS AFTER ORAL ADMINISTRATOR: KENNETH C. CUNDY ET AL. CATION SERIAL NO: 09/972,425 5 OF 31

FIG. 6

HOW 
$$(XIII)$$
  $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_2$   $R_4$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_2$   $R_3$   $R_4$   $R_5$   $R_5$   $R_6$   $R_9$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_1$   $R_2$   $R_1$   $R_1$   $R_2$   $R_3$   $R_4$   $R_1$   $R_1$   $R_2$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_1$   $R_2$   $R_2$   $R_3$   $R_4$   $R_1$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_1$   $R_1$   $R_2$   $R_1$   $R_2$   $R_1$   $R_2$   $R_1$   $R_2$   $R_1$   $R_2$   $R_2$   $R_1$   $R_2$   $R_1$   $R_2$   $R_1$   $R_2$   $R_1$   $R_2$   $R_2$   $R_3$   $R_4$   $R_1$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_1$   $R_2$   $R_2$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_1$   $R_1$   $R_2$   $R_1$   $R_1$   $R_1$ 

R1 =  $\alpha$ -OH; R2 =  $\alpha$ -OH (Cholate)

R1 =  $\beta$ -OH; R2 = H (Ursodeoxycholate) R1 =  $\alpha$ -OH; R2 = H (Chenodeoxycholate)


R1 = H; R2 =  $\alpha$ -OH (Deoxycholate)

R1 =  $\beta$ -OH; R2 =  $\alpha$ -OH (Ursocholate)

R1 = H; R2 = H (Lithocholate)


OGGVEHES OEOSOE

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATION OF DRUGS AFTER ORAL ADMINISTRATION. KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 6 of 31



R1 = 
$$\alpha$$
-OH; R2 =  $\alpha$ -OH (Cholate) Y =  $\alpha$ -O Z = OH  
R1 =  $\beta$ -OH; R2 = H (Ursodeoxycholate) Y =  $\beta$ -O Z = OH  
R1 =  $\alpha$ -OH; R2 = H (Chenodeoxycholate) Y =  $\alpha$ -NH  
R1 = H; R2 =  $\alpha$ -OH (Deoxycholate) Y =  $\beta$ -NH  
R1 =  $\beta$ -OH; R2 =  $\alpha$ -OH (Ursocholate) Y =  $\beta$ -NH  
R1 = H; R2 = H (Lithocholate)


APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATION OF DRUGS AFTER ORAL ADMINISTRATIO
INVENTE: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 7 OF 31





R1 =  $\beta$ -OH; R2 = H (Ursodeoxycholate) Y =  $\beta$ -O Z = OH R1 =  $\alpha$ -OH; R2 = H (Chenodeoxycholate) Y =  $\alpha$ -NH R1 = H; R2 =  $\alpha$ -OH (Deoxycholate) Y =  $\beta$ -NH R1 =  $\beta$ -OH; R2 =  $\alpha$ -OH (Ursocholate) Y =  $\beta$ -NH R1 = H; R2 = H (Lithocholate) APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATICK OF DRUGS AFTER ORAL ADMINISTRATI
IN OR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 8 OF 31

8/31


FIG. 9 Uptake of (8) (XP10569) or Glycochocholate by IBAT-Transfected CHO Cells









APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATIOMS OF DRUGS AFTER ORAL ADMINISTRATION
IN DR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 9 OF 31




APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATION OF DRUGS AFTER ORAL ADMINISTRATION: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 10 of 31




TITLE: BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION INVENTION SERIAL NO: 09/972,425 11 of 31



APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATION OF DRUGS AFTER ORAL ADMINISTRAT
IN FOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 12 of 31



APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRATION F DRUGS AFTER ORAL ADMINISTRATIO
INVENTE: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 13 OF 31



TITLE: BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATIONS. KENNETH C. CUNDY ET AL.

## 14/31


(214) 
$$(43)$$
  $(44)$   $(44)$   $(44)$   $(20)$   $($ 

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTRA
TION F DRUGS AFTER ORAL ADMINISTRATION
INVENTA: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 15 of 31

oggretes. Cecce

(54)

...OH




APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVERING SUSTAINED SYSTEMIC CONCENTRATION DE DRUGS AFTER ORAL ADMINISTRATION
INVENSOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 17 OF 31

17/31

R=H (56) R=Me (57 APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROMUNG SUSTAINED SYSTEMIC CONCENTRATION OF DRUGS AFTER ORAL ADMINISTRATION.

INV. OR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 18 OF 31



APPLING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTY
OF DRUGS AFTER ORAL ADMINISTRAT
IN AFOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 19 of 31

19/31

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVENING SUSTAINED SYSTEMIC CONCENTRA
TION DRUGS AFTER ORAL ADMINISTRATION
INVEN : KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 20 of 31


20/31

 $Y=3\alpha-0 (96)$   $Y=3\beta-0 (97)$   $Y=3\alpha-NH (98)$ Y=3eta –NH (99) $3\alpha - 0$  (102)  $3\beta - 0$  (103) ,,,OH n=1-5 Y=3 $\alpha$  -0 (92) Y=3 $\beta$  -0 (93) Y=3 $\alpha$  -NH (94) Y=3 $\beta$  -NH (95)  $3\alpha - 0$  (100)  $3\beta - 0$  (101) n=1-5 FIG. 22

Compounds (92)-(103) prepared following methods described in co-pending application "Bile Acid-Derived Compounds for Enhancing Oral Absorption and Systemic Bioavailability of Drugs" assigned to XenoPort, Inc.

1997E4E5 OEOSOE


APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTR
OF DRUGS AFTER ORAL ADMINISTRAT
IN FOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 21 of 31



APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROPUDING SUSTAINED SYSTEMIC CONCENTR
THE OF DRUGS AFTER ORAL ADMINISTRATI
INVESTOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 22 of 31

22/31

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENTY
OF DRUGS AFTER ORAL ADMINISTRAT
INVENTOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 23 OF 31



24/31 2. **(39)**, Toluene, ∆ 2. Piperidine, CH<sub>2</sub>Cl<sub>2</sub> 1. PPTs, MeOH, ∆ 1. **(39)**, Toluene, ∆ (126) 3. TFA (109) ZI (123) 3.  $Na^+$  exchange resin  $H_2O/MeOH$ 1. CICO<sub>2</sub>Et NBu<sub>3</sub>, dioxane 2. Taurine, H<sub>2</sub>0 FIG. 26 Ó-THP (125) $2,4,6-Cl_3C_6H_2C(0)Cl_2$ Et<sub>3</sub>N, DMAP, (108) (96)

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROYIDING SUSTAINED SYSTEMIC CONCENTRATION OF DRUGS AFTER ORAL ADMINISTRATION. OR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 25 of 31

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVIDING SUSTAINED SYSTEMIC CONCENT
TO OF DRUGS AFTER ORAL ADMINISTRAT
INVENTOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 26 of 31

26/31

1. (2), Dioxane,  $Na_2HPO_4$ 4. Na<sup>†</sup>exchange resin H<sub>2</sub>0/Me0H 2. Optionally CH<sub>2</sub>N<sub>2</sub> TFA ∾. 0  $Y=3\beta-NH(142)$  $Y=3\alpha - NH(141$ Y=3α-0**(139**  $Y=3\beta-0$ R=Me, R=Me, R=Me, R=Me, 0  $Y=3\beta-NH$  $Y=3\alpha-NH$ Y=3α-0  $Y=3\beta-0$ FIG. 28 R=H. R=H, R=H, R=H, Hg0, CH<sub>2</sub>Cl<sub>2</sub> (131)–(134)

(56)

 $Y=3\beta-0$ Y=3α -NH(  $Y=3\beta-NH$  $Y=3\alpha-0$ R=Me, R=Me, R'=Me, R=Me, R′=Me, I R′=Me, ∣ R′=Me,  $Y=3\beta-NH$  (154) (151) $Y=3\alpha-NH$ Y=3β-0 (  $Y=3\alpha-0$ R=H, R=H, R=H, R=H, R′=Me, ∣ R′=Me, ∣ R′=Me, R′=Me, (150)R=Me, Y=3α-NH(149)  $Y=3\beta-0(148)$ R=Me, Y=3α-0(147  $Y=3\beta-NH$ R=Me, R=Me, R'=Na, R′=Na, R'=Na, R'=Na, Y=3 $\beta$  -0 (144) Y=3 $\alpha$ -NH (145)  $Y=3\beta-NH$  (146) Y=3α-0 (143 R=H, R=H, R=H, R'=Na, R′=Na, R'=Na, R'=Na,

2

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROBLIDING SUSTAINED SYSTEMIC CONCENTE
THE OF DRUGS AFTER ORAL ADMINISTRATI
INVESTOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 27 of 31

27/31

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROJUCING SUSTAINED SYSTEMIC CONCENTS
TO OF DRUGS AFTER ORAL ADMINISTRAT
INVENTOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 28 of 31


28/31  $Y=3\alpha - NH (186)$  $Y=3\beta-NH(187)$  $Y=3\beta -0(185)$ Y=3α -0 ( R=Bn, R=Bn, R=Bn, R=Bn,  $Y=3\beta - NH(195)$ R=Bn, Y=3 $\alpha$  -NH (194 R=Bn, Y=3 $\alpha$  -0 (192) R=Bn, Y=3 $\beta$  -0 (193) R=Et, Y=3 $\beta$ -NH (183)  $Y=3\alpha-NH$  (182) (188) (188)  $Y=3\beta-0$  (181) Y=3α-0 ( R=Bn, RNH, DMSO R=Et, R=Et, R=Et, R=Et, Y=3α-NH (190) Y=3 $\beta$ -NH (191 R=Et, Y=3 $\alpha$ -0 (188) R=Et, Y=3 $\beta$  -0 (189) CO2tBu  $Y=3\beta - NH (179)$  $Y=3\alpha-0$  (176  $Y=3\beta-0$  (1) $Y=3\alpha-NH$ R=Et, Piperidine,  $CH_2Cl_2$  (for (43))  $co_2R'$  (39)or (43), Toluene, ∆ Na<sup>+</sup> exchange resin Bromoacetic anhydride F/G. 30 H<sub>2</sub>0/Me0H  $CO_2H$ OSiMe 3 DIC, DMF <u>∝</u> MeCN, DMAP 2. py.HF 7 4 ω.

R=Bn Y=3 $\beta$  -0 (209) R=Bn Y=3 $\alpha$  -NH(210) R=Bn Y=3 $\beta$ -NH(211 R=Bn Y=3α-0**(208** R'=Na, R'=Na, R'=Na, K'=Na,  $Y=3\alpha-NH(206)$ Y=3  $\beta$ -NH(207  $Y=3\beta-0(205)$  $Y=3\alpha-0(204)$ R=Et, R=Et, . R=Et, . R=Et, R'=Na, R'=Na, R'=Na, R=Bn Y= $3\alpha$ -NH(202) R=Bn Y=3 $\alpha$ -0(200) R=Bn Y=3 $\beta$ -0(201)  $Y=3\beta-NH$ R=Bn R′=Me, R′=Me, ∣ R′=Me, R′=Me,  $Y=3\alpha - NH(198)$  $Y=3\beta - NH(199)$ Y=3α -0(196)  $Y=3\beta-0(197)$ R=Et, R=Et, R=Et, R′=Me, R′=Me, R′=Me, K′=Me,

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROVE ING SUSTAINED SYSTEMIC CONCENTRA
TIOL F DRUGS AFTER ORAL ADMINISTRATION
INVENTOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 29 of 31

29/31

APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROPUDING SUSTAINED SYSTEMIC CONCENTR
TICE OF DRUGS AFTER ORAL ADMINISTRATION
INVESTOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 30 of 31



APPLN FILING DATE: OCT. 5, 2001 033053-025
TITLE: BILE-ACID DERIVED COMPOUNDS FOR
PROTEING SUSTAINED SYSTEMIC CONCENTRA
TIOL F DRUGS AFTER ORAL ADMINISTRATIO
INVENTOR: KENNETH C. CUNDY ET AL.
APPLICATION SERIAL NO: 09/972,425 31 OF 31